company background image
CTKB logo

Cytek Biosciences NasdaqGS:CTKB Stock Report

Last Price

US$6.24

Market Cap

US$828.3m

7D

-4.9%

1Y

-33.1%

Updated

18 Dec, 2024

Data

Company Financials +

Cytek Biosciences, Inc.

NasdaqGS:CTKB Stock Report

Market Cap: US$828.3m

CTKB Stock Overview

A cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. More details

CTKB fundamental analysis
Snowflake Score
Valuation3/6
Future Growth4/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Trading at 88.3% below our estimate of its fair value

Earnings are forecast to grow 114.67% per year

Analysts in good agreement that stock price will rise by 34.6%

Risk Analysis

Volatile share price over the past 3 months compared to the US market


My Notes

Capture your thoughts, links and company narrative

Cytek Biosciences, Inc. Competitors

Mesa Laboratories

NasdaqGS:MLAB

US$718.7m

Pacific Biosciences of California

NasdaqGS:PACB

US$539.5m

Adaptive Biotechnologies

NasdaqGS:ADPT

US$962.2m

Standard BioTools

NasdaqGS:LAB

US$822.7m

Price History & Performance

Summary of share price highs, lows and changes for Cytek Biosciences
Historical stock prices
Current Share PriceUS$6.24
52 Week HighUS$9.87
52 Week LowUS$4.66
Beta1.46
1 Month Change3.48%
3 Month Change17.96%
1 Year Change-33.12%
3 Year Change-63.40%
5 Year Changen/a
Change since IPO-66.74%

Recent News & Updates

Is Cytek Biosciences (NASDAQ:CTKB) Weighed On By Its Debt Load?

Dec 16
Is Cytek Biosciences (NASDAQ:CTKB) Weighed On By Its Debt Load?

Investors Still Aren't Entirely Convinced By Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Revenues Despite 46% Price Jump

Nov 07
Investors Still Aren't Entirely Convinced By Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Revenues Despite 46% Price Jump

Recent updates

Is Cytek Biosciences (NASDAQ:CTKB) Weighed On By Its Debt Load?

Dec 16
Is Cytek Biosciences (NASDAQ:CTKB) Weighed On By Its Debt Load?

Investors Still Aren't Entirely Convinced By Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Revenues Despite 46% Price Jump

Nov 07
Investors Still Aren't Entirely Convinced By Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Revenues Despite 46% Price Jump

Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Shares Not Telling The Full Story

Sep 13
Cytek Biosciences, Inc.'s (NASDAQ:CTKB) Shares Not Telling The Full Story

An Intrinsic Calculation For Cytek Biosciences, Inc. (NASDAQ:CTKB) Suggests It's 49% Undervalued

Aug 09
An Intrinsic Calculation For Cytek Biosciences, Inc. (NASDAQ:CTKB) Suggests It's 49% Undervalued

Is Cytek Biosciences (NASDAQ:CTKB) Using Debt Sensibly?

Jul 12
Is Cytek Biosciences (NASDAQ:CTKB) Using Debt Sensibly?

Potential Upside For Cytek Biosciences, Inc. (NASDAQ:CTKB) Not Without Risk

Jun 04
Potential Upside For Cytek Biosciences, Inc. (NASDAQ:CTKB) Not Without Risk

Cytek Biosciences: Undisputed Next-Gen Flow Cytometry Leader

Mar 20

Cytek Biosciences' (NASDAQ:CTKB) Solid Profits Have Weak Fundamentals

Mar 08
Cytek Biosciences' (NASDAQ:CTKB) Solid Profits Have Weak Fundamentals

Cytek Biosciences Vs. 10x Genomics: 2 Opposing Cell Visualization Investments

Jul 27

Checking In On Cytek Biosciences

Mar 23

Shareholder Returns

CTKBUS Life SciencesUS Market
7D-4.9%-1.5%0.1%
1Y-33.1%-3.7%26.1%

Return vs Industry: CTKB underperformed the US Life Sciences industry which returned -3.7% over the past year.

Return vs Market: CTKB underperformed the US Market which returned 26.1% over the past year.

Price Volatility

Is CTKB's price volatile compared to industry and market?
CTKB volatility
CTKB Average Weekly Movement12.2%
Life Sciences Industry Average Movement9.2%
Market Average Movement6.3%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.1%

Stable Share Price: CTKB's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: CTKB's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1992645Wenbin Jiangcytekbio.com

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils.

Cytek Biosciences, Inc. Fundamentals Summary

How do Cytek Biosciences's earnings and revenue compare to its market cap?
CTKB fundamental statistics
Market capUS$828.25m
Earnings (TTM)-US$10.16m
Revenue (TTM)US$201.21m

4.0x

P/S Ratio

-79.1x

P/E Ratio

Is CTKB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CTKB income statement (TTM)
RevenueUS$201.21m
Cost of RevenueUS$90.71m
Gross ProfitUS$110.50m
Other ExpensesUS$120.66m
Earnings-US$10.16m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.079
Gross Margin54.92%
Net Profit Margin-5.05%
Debt/Equity Ratio0.8%

How did CTKB perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 23:20
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cytek Biosciences, Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kyle MiksonCanaccord Genuity
Matthew SykesGoldman Sachs
Tejas SavantMorgan Stanley